Prostate Cancer
Trial Number: 78278343PCR3001 (KLK2-comPAS) Protocol Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T cell redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.
- Details
ClinicalTrials.gov ID:
NCT07164443
Diagnosis Type:
NA
USOR Number:
- Address
,
P: